COMMUNIQUÉS West-GlobeNewswire

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/03/2026
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation [...]
VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results
12/03/2026
TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has updated the date for the release of its financial results for the fourth [...]
Voting Rights and Shares Capital of the Company
12/03/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, March 12, 2026 (GLOBE NEWSWIRE [...]
Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
12/03/2026
MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
12/03/2026
MISSISSAUGA, Ontario, March 12, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on [...]
Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results
12/03/2026
Full-Year Net Revenue Increased 33% Y-O-Y to $18.8 Million and Fourth-Quarter Net Revenue up 22% Y-O-Y to $4.7 Million Reports Second Consecutive Year of Positive Net Income SOUTH ORANGE, N.J., March 12, 2026 (GLOBE [...]
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations -- Next-generation PI3K α pan-mutant inhibitor development candidate for [...]
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
12/03/2026
Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy [...]
TerrAscend Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Net Revenue of $66.1 million for Q4 2025 and $260.6 Million for FY 2025 Gross Profit Margin of 52.1% for Q4 2025 and 52.3% for FY 2025 from continuing operations Q4 2025 Net Cash provided from continuing operations of $ [...]
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib [...]
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
12/03/2026
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for [...]
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
12/03/2026
Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026 Fewer disease [...]
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
12/03/2026
Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells (“DRI [...]
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected [...]
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
12/03/2026
The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq [...]
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
12/03/2026
Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) [...]
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
12/03/2026
BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director [...]
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
12/03/2026
Conference Call to be held on April 2nd, 2026 at 5:00 PM EST NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q4 and year end [...]
The Ensign Group to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 19, 2026
12/03/2026
SAN JUAN CAPISTRANO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and provide skilled nursing and senior living [...]

Pages